Matthew Caufield
Stock Analyst at H.C. Wainwright
Total Price Targets
8
Stocks Covered
6
Sectors
Healthcare
Most Recent
Mar 27, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Matthew Caufield
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| KOD | Kodiak Sciences Inc. | $58.00 | $44.09 | +31.5% | 2 | Mar 27, 2026 |
| MLYS | Mineralys Therapeutics, Inc. | $56.00 | $29.07 | +92.7% | 2 | Mar 10, 2026 |
| LENZ | LENZ Therapeutics, Inc. | $56.00 | $8.85 | +533.1% | 1 | Oct 27, 2025 |
| DMAC | DiaMedica Therapeutics Inc. | $7.00 | $6.21 | +12.7% | 1 | Oct 7, 2024 |
| FDMT | 4D Molecular Therapeutics, Inc. | $36.00 | $9.17 | +292.6% | 1 | Sep 19, 2024 |
| PHAT | Phathom Pharmaceuticals, Inc. | $28.00 | $11.73 | +138.7% | 1 | Jul 19, 2024 |
Recent Activity
- Mar 27, 2026— Set$58.00price target onKOD(Kodiak Sciences Inc.)
- Mar 10, 2026— Set$56.00price target onMLYS(Mineralys Therapeutics, Inc.)
- Jan 22, 2026— Set$38.00price target onKOD(Kodiak Sciences Inc.)
- Oct 27, 2025— Set$56.00price target onLENZ(LENZ Therapeutics, Inc.)
- Apr 2, 2025— Set$42.00price target onMLYS(Mineralys Therapeutics, Inc.)
- Oct 7, 2024— Set$7.00price target onDMAC(DiaMedica Therapeutics Inc.)
- Sep 19, 2024— Set$36.00price target onFDMT(4D Molecular Therapeutics, Inc.)
- Jul 19, 2024— Set$28.00price target onPHAT(Phathom Pharmaceuticals, Inc.)
Frequently Asked Questions
Who is Matthew Caufield?
Matthew Caufield is a stock analyst at H.C. Wainwright covering 6 stocks primarily in Healthcare. They have issued 8 price targets since Jul 19, 2024.
What stocks does Matthew Caufield cover?
Matthew Caufield currently covers 6 stocks, including KOD, MLYS, LENZ, DMAC, FDMT.
What is Matthew Caufield's latest price target?
Matthew Caufield's most recent price target was $58.00 on KOD (Kodiak Sciences Inc.), set on Mar 27, 2026.
What is Matthew Caufield's highest price target?
Matthew Caufield's highest issued price target is $58.00 on KOD, set on Mar 27, 2026.
More Analysts at H.C. Wainwright
Coverage based on publicly published price targets. Not investment advice.